Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

'I Am Doing Well': Bayern Star Jamal Musiala Reveals Treatable Absence Seizure Diagnosis After Back-To-Back Collapses | Video

Berlin: Bayern Munich star Jamal Musiala revealed that he had been diagnosed with absence seizures after collapsing once again during his side's match on Tuesday. TRENDING: Bayern Munich's Jamal Musiala collapsed on the pitch and Ismael Saibari immediately stepped in. pic.twitter.com/btYIAXeBPd — Polymarket Sports (@PolymarketSport) August 16, 2026 In Bayern's 4-2 win over Heidenheim, Jamal once…

'I Am Doing Well': Bayern Star Jamal Musiala Reveals Treatable Absence Seizure Diagnosis After Back-To-Back Collapses | Video

Bayern Munich player Jamal Musiala announced that he has been diagnosed with absence seizures after collapsing twice during matches on Tuesday. The incidents occurred during Bayern's 4-2 victory over Heidenheim, as well as a friendly against RB Leipzig. Both teams formed a circle around Musiala, and medical staff attended to him, allowing him to leave the pitch unassisted.

On Instagram, Musiala shared that the seizures are treatable and caused by a neurological disorder, and he is currently doing well. The 25-year-old, who joined Bayern in 2020, has won six Bundesliga titles and a UEFA Champions League trophy. He was also part of Germany's FIFA World Cup 2026 squad, which was eliminated in the round of 32.

Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Also reported by 1 other outlet

Read the original at freepressjournal.in →

More in Health & Medicine

SK Biopharmaceuticals Settles XCOPRI U.S. Patent Dispute

SK Biopharmaceuticals announced on August 19 that it has reached an amicable settlement with the Indian generic company MSN Laboratories in a United States patent litigation regarding its innovative…

  • SK Biopharmaceuticals settles patent dispute with MSN Laboratories.
  • Agreement allows MSN Laboratories to market generic cenobamate (XCOPRI) under patent.
  • Settlement resolves pending litigation at Delaware District Court.

More from Wednesday 19 August →